Vaccination Against Androgen Receptor Splice Variants to Immunologically Target Prostate Cancer.

ABSTRACT: Background/Objectives: Androgen receptor (AR) expression and signaling are critical for the progression of prostate cancer and have been the therapeutic focus of prostate cancer for over 50 years. While a variety of agents have been developed to target this axis, many of these fail due to the emergent expression of AR RNA splice variants, such as AR-V7, that can signal independently of ligand binding. Other therapies, such as vaccination against prostate-specific antigens, have achieved FDA approvals but have fallen short of being incorporated as standard-of-care therapies for advanced prostate cancer. This may be due to the elevated level of immunosuppression observed in prostate cancer, which remains largely refractory to immune checkpoint blockade. Methods: We developed a

SUBMITTER: Marek RD 

PROVIDER: S-EPMC11599078 | biostudies-literature | 2024 Nov

REPOSITORIES: biostudies-literature